Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by logical1234on Mar 19, 2002 6:52pm
308 Views
Post# 4900812

Synsorb press release

Synsorb press releaseCox and some other directors are resigning. New directors say they want to maintain Synsorb as a going concern. (?Or could be a smokescreen to get a better bid for the company?) I don't see any immediate impact on ONC. SYB's directors aren't likely to do anything at least until after their special meeting. ---- CALGARY, March 19 /CNW/ - SYNSORB Biotech Inc. ("SYNSORB") (NASDAQ: SYBB) (TSE: SYB), today announced that its Board of Directors has approved immediate changes to the Board of Directors and senior management of the Company. Effective immediately, Bill Hogg, currently the Vice President Finance and Chief Financial Officer will assume the role of President & CEO, in addition to his existing responsibilities. Mr. Hogg has also been elected to the Board of Directors. Dr. David Cox, formerly the President & CEO will be leaving the Company at the end of March to pursue other opportunities, but will continue in a part-time consulting role until July 31, 2002. Dr. Cox remains as a member of the Board of Directors, but will not stand for re-election as a director at the Annual General Meeting (AGM), to be held on May 7, 2002. Mr. Froom, Vice President, Business Development and Dr. Ratcliffe, Vice President R&D and Manufacturing, had previously left the Company. Mr. Richard Casey has resigned as Chairman of the Board and Mr. Gerry Quinn has been elected as Chairman. Effective immediately, Mr. Campbell, Mr. Casey, and Dr. Crooke have resigned as directors of the Company. The SYNSORB Board of Directors will nominate Mr. Hogg, Mr. Quinn and Mr. Kenway to stand for re-election as directors of the Company at the AGM, and the number of directors will be reduced to three. "These changes are prudent and appropriate for SYNSORB under the current circumstances," said Gerry Quinn, the new Chairman of the Board. "We have made considerable progress in reducing costs to a minimum. SYNSORB may return a portion of its assets directly to our shareholders. However, it is our intention to remain as a going concern, and to continue as a public company. The Company, with its $85 million of tax pools and its other assets, presents an excellent vehicle for new business development." "I would also like to take this opportunity to thank the retiring directors and departing staff for all of their support and years of service to the Company," said Mr. Quinn. "In particular, Dr. Cox has shouldered a heavy burden during the past months, and we wish him well in his future endeavours." Mr. Quinn has served as a director of SYNSORB since January 16, 1995. He has been the President of The Erin Mills Investment Corporation, a venture capital company, since July 1, 1989. Mr. Quinn holds a BSc. in Chemistry and is a Chartered Accountant. He has previously been a partner in a national accounting firm, where he specialized in corporate restructuring activity. Bill Hogg has been SYNSORB's Vice President, Finance and Chief Financial Officer since March 26, 2001 and prior thereto he was Senior Vice President and Chief Financial Officer of Dominion Energy Canada Limited. He became a member of the Canadian Institute of Chartered Accountants in 1978, and holds a M.B.A. from the University of Calgary. SYNSORB Biotech Inc. is a publicly traded company listed on both the Toronto Stock Exchange (symbol SYB) and on Nasdaq National Markets (ticker SYBB).
Bullboard Posts